Sales & Marketing News | pharmaphorum

News

Sandoz will pay $265m to settle price fixing case in US

Generic and biosimilar drug producer Sandoz has agreed a $265 million settlement that aims to put allegations of price-fixing brought in a Pennsylvania lawsuit behind

News

Viatris splashes out $350m on pair of Idorsia therapies

Viatris has made a play to expand its branded medicines business by licensing two late-stage drugs from Idorsia – for acute myocardial infarction (AMI) and systemic lupus

News

Minerva slumps as FDA finds fault with schizophrenia filing

Shares in Minerva Neurosciences have lost more than half their value after the FDA rejected its marketing application for roluperidone as a treatment for the negative symp

News

FDA says yes to Allecra, no to Venatorx UTI drugs

The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs) that will now launch later this year, but tu

News

CHMP backs AZ’s danicopan for anaemia in patients with PNH

AstraZeneca has moved a step closer to EU approval of oral Factor D inhibitor danicopan in the EU, after the EMA’s human medicines committee, the CHMP, backed the drug as

News

Interchangeable high-concentration Humira approved in US

For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulat

Sandoz will pay $265m to settle price fixing case in US

Viatris splashes out $350m on pair of Idorsia therapies

Minerva slumps as FDA finds fault with schizophrenia filing

FDA says yes to Allecra, no to Venatorx UTI drugs

CHMP backs AZ’s danicopan for anaemia in patients with PNH

Interchangeable high-concentration Humira approved in US

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks